Maria Jose

Dr. Maria Jose

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Current Drug Safety
Verified
Journal Article
Closed access
PDF file
PRPriyanka Rajmohan
Priyanka Rajmohan
MJMaria Jose
Maria Jose
JTJoe Thomas
Joe Thomas
SNSwathi Krishna Njarekkattuvalappil
Swathi Krishna Njarekkattuvalappil
BABeena Antony
Beena Antony
PKPraveenlal Kuttichira
Praveenlal Kuttichira
Background: The reports on adverse experiences following vaccination are scanty from India. It is important to know the real-world post-vaccination experience outside of clinical trial conditions. Objectives: The study aims to estimate the incidence of adverse events following immunization with the ChAdOx1 nCoV-19 coronavirus vaccine and to identify the predictors for the development of vaccine adverse events. Methods: A prospective observational study was conducted among health care workers who received the ChAdOx1 nCoV-19 coronavirus vaccine. Study participants were monitored at the site for 30min following vaccination and were followed up for 7 days after receiving the second dose, with a purpose-specific designed online surveillance form to enquire about any adverse events following vaccination. We used the Chi-squared test for categorical variables and multivariate regression analysis to identify predictors for the development of vaccine adverse effects. Results: Of 411 participants, the mean age was 30.77 +/- 12.5 years and 76.2% were females. Overall, 207 (50.4%) respondents reported at least one post-vaccination symptom receiving either dose of coronavirus vaccination. Fever (34.8%), local pain at the injection site (28.0%), tiredness (25.5%), chills (20%), myalgia (18.7%), headache (17.8%), injection site stiffness (5.4%), joint pain (4.6%) and nausea-vomiting (3.8%) were the most prevalent symptoms following the first dose. Adverse reactions reported after the second dose were milder and less frequent. Post-vaccination symptoms were more likely in the younger age group, those with comorbidity particularly, bronchial asthma, and a history of allergy to food/drugs. Conclusion: All the adverse reactions were of a minor type and non-serious. Side effects were less common in older adults (>60 years). Reactions to the second dose were lesser in intensity and frequency. Younger age, history of allergy, and comorbidities, particularly asthma, were found to be major predictors for the development of adverse events and require more watchful vaccine administration.

14 May 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MJMaria Jose
Maria Jose
PRPriyanka Rajmohan
Priyanka Rajmohan
TST. S. Sulfath
T. S. Sulfath
RVRavi Prasad Varma
Ravi Prasad Varma
MMManoj Mohan
Manoj Mohan
JTJoe Thomas
Joe Thomas
Introduction: NCDs arise from complex interactions of modifiable factors such as unhealthy lifestyles, poor diet, and psychosocial challenges, along with non-modifiable factors like age and genetics. Notably, medication non-adherence is a widespread and growing concern, significantly contributing to disease progression and poor outcomes globally. Objective: This scoping review aims to synthesize evidence on medication adherence scales used for selected non communicable diseases. It examines their development methods, psychometric properties, and assessed domains, while identifying gaps or limitations in their design and application. Materials and methods: The Joanna Briggs Institute methodological framework guided this scoping review and the protocol was registered prospectively to ensure methodological transparency and rigor. Electronic databases, the reference list of included articles, and grey literature were searched. Studies published in English from January 1950 to June 2024 were included. Two reviewers independently screened all articles, and a third reviewer settled any conflicts between the reviewers. Critical appraisal of the screened-in articles was done using JBI critical appraisal scales. The data was compiled into tables and a narrative summary that is consistent with the review’s goal. Results: Our study included 140 articles, identifying 57 medication adherence scales. These scales, developed using qualitative methods (10.8%), literature review (32.4%), and mixed methods (45.9%), primarily focus on behavior, often neglecting cost-related non-adherence, self-efficacy, and systemic barriers. Psychometric findings varied widely, reflecting heterogeneity in study designs and scale development approaches. Many scales lack validation in diverse settings, underscoring the need for comprehensive, context-sensitive tools. Conclusion: This scoping review highlights gaps in existing medication adherence scales for NCDs, particularly their limited consideration of socioeconomic and cultural factors and incomplete adherence assessment. Future research should focus on developing more holistic, contextually relevant adherence scales that integrate these dimensions. Strengthening adherence measurement methodologies can enhance patient-centered care, inform policy interventions, and improve health outcomes.

3 December 2024 in JMIR Research Protocols
Verified
Journal Article
Open access
JTJoe Thomas
Joe Thomas
MJMaria Jose
Maria Jose
PRPriyanka Rajmohan
Priyanka Rajmohan
FFFarah Naaz Fathima
Farah Naaz Fathima
HMHisham Moosan
Hisham Moosan
RPRavi Prasad Varma P
Ravi Prasad Varma P
Background: In high-income countries, only 50% of patients treated for chronic diseases adhere to the prescribed treatment. This issue is even more pronounced in resource-limited countries. Medication adherence scales are simple, low-cost approaches to identify nonadherence in clinical practice. In India, nonadherence to medication varies from 18.7% to 74%, assessed using scales validated in the Western population, as there is no validated medication adherence tool contextualized to the Indian setting. The phrasing of questions in scales validated elsewhere and its interpretations may vary when applied in Indian patients unless accounting for the unique cultural, social, and economic factors influencing medication adherence in India. This could result in inaccurate reports of adherence behavior. Objective: This study aims to develop and validate a novel medication adherence tool for select noncommunicable diseases (diabetes mellitus, hypertension, chronic obstructive pulmonary disease, bronchial asthma, and coronary artery disease) in the Indian population. Methods: An exploratory sequential mixed methods design will be used, beginning with a qualitative phase where the construct of the scale is defined and preliminary items are generated through a scoping review, focus group discussions, and in-depth interviews. This will be followed by the tool’s development phase, including an expert panel review and item revision. Finally, a quantitative phase in 4 zones in India (North, South, East, and West) will be conducted to confirm and validate the newly developed scale. Results: In the first phase, we will frame the construct definition and develop an inventory of potential items for the proposed medication adherence tool. In the second phase, item-level and scale-level content validity indices, along with content validity ratio, will be estimated. In the third phase, we will conduct an item reduction analysis and determine the scoring matrix and item weightage after expert review. We will assess the tool's psychometric properties, plot the receiver operating characteristic (ROC) curve to set an adherence cut-off score, and compute the construct validity and test-retest reliability from the quantitative survey. Conclusions: A medication adherence tool for noncommunicable diseases, developed after ensuring it is ethnically, culturally, and linguistically appropriate incorporating stakeholder perspectives and validated in community settings, would offer a real-world perspective of adherence. The tool will have 2 versions for clinical practice and research, aiding policy makers in adopting tailored adherence policies. International Registered Report Identifier (IRRID): PRR1-10.2196/60805

25 August 2023 in International Journal of Basic & Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
VKVineeth V. K.
Vineeth V. K.
MJMaria Jose
Maria Jose
Misoprostol (PGE1) is a drug that is very commonly used in obstetrics for labour induction. Apart from its side effect of causing congenital malformations in offspring of users who have unsuccessfully used it as an abortifacient, it is considered a safe drug with few side effects. We here report a severe hypersensitivity reaction to misoprostol in a 33-year-old term pregnant patient who is non-allergic to vaginal misoprostol. The patient developed anaphylactic features like swelling of lips, low voice due to laryngeal oedema, and bradycardia. Prompt administration of adrenaline and emergent caesarean section allowed for the safe delivery of the neonate. When inducing labour, quick identification and treatment of anaphylaxis and hypersensitivity reactions are necessary to prevent maternal and neonatal morbidity and mortality.

8 August 2026 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Closed access
PDF file
PRPriyanka Rajmohan
Priyanka Rajmohan
JTJoe Thomas
Joe Thomas
MJMaria Jose
Maria Jose
TST. S. Sulfath
T. S. Sulfath
RVRavi Prasad Varma
Ravi Prasad Varma
JCJerin Jose Cherian
Jerin Jose Cherian

1 July 2026 in Journal of Acute Disease
Verified
Journal Article
Open access
SPSherin Joseph Ponthokkan
Sherin Joseph Ponthokkan
MPMarin Paulson
Marin Paulson
CVChithra Valsan
Chithra Valsan
MJMaria Jose
Maria Jose
Objective: To assess the appropriateness of surgical antibiotic prophylaxis (SAP) use and its adherence to institutional guidelines, and to identify factors associated with surgical site infection (SSI) occurrence in lower segment caesarean section (LSCS) patients. Methods: A prospective observational study was conducted among women undergoing LSCS in Jubilee Mission Medical College and Research Institute, Thrissur, India. SAP appropriateness (antibiotic selection, timing, and duration) was evaluated, and participants were followed for six weeks postoperatively. Associations with SSI were analysed using chi -square and Fisher’s exact tests. Results: The overall SSI rate among the 80 women was 15.0%, all superficial. SAP adherence was 60.0% for antibiotic choice, 55.0% for timing, and 53.8% for duration. Younger women (⩽30 years) had significantly higher SSI rates compared with older women (21.6% vs 3.4%; P =.04). No significant association was observed between SSI and gestational diabetes, timing category, or antibiotic regimen group. Emergency LSCS had a higher SSI incidence than elective procedures (22.7% vs 5.6%; P =.03). The predominant organisms isolated were Escherichia coli , Klebsiella spp., and Staphylococcus aureus . Conclusions: Gaps in SAP adherence particularly in antibiotic selection and timing were identified, with younger age and emergency surgery associated with higher SSI occurrence. Ensuring the availability of recommended first-generation cephalosporins, standardising SAP protocols, and strengthening antimicrobial stewardship are essential to improve surgical outcomes following LSCS and reduce antimicrobial resistance.